Scouting report · NKTR

Linda M. Rubinstein

FLG Partners consultant; Nektar's interim CFO since May 2026

Born / age
(59)
Role
Interim CFO (principal financial and accounting officer)
In the role
5 mo
Education
BA University of California, Los Angeles
Front Office rank
not ranked yet
NKTR
Nektar TherapeuticsBiotech binary
Title
Interim CFO (principal financial and accounting officer)src
In role
since 2026-05 (5 mo)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 25 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design—no proxy read yet
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Linda M. Rubinstein
Age
59src
Education
BA Economics, University of California, Los Angelessrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
0 NKTR, 2026-05-15src
Share of company
0%
Traded, 12 months
bought $0, sold $0src

What to weigh

Watch 2

  • Nektar has had no permanent CFO since at least April 2023: two FLG consultants in a row (Gardiner, then Rubinstein), while the company raised $460m in February 2026 and put a new ATM in place in Maysrc
  • No skin in the game: her Form 3 reports no Nektar securities owned, and as a consultant she gets no Nektar bonus or equity (her predecessor held none either)src

In their favour 1

  • Put her own money into Adverum in 2023 through an open-market purchase while CFO theresrc

Career

  1. 2026 – now
    Nektar Therapeuticssrc
    Interim CFO, via FLG Partners
    Effective 2026-05-15; signed the Q2 2026 10-Q as principal financial officer (10Q-2026-Q2)
  2. 2022 – 2025
    Adverum Biotechnologiessrc
    CFO, principal financial and accounting officer, via FLG Partners
    Appointed 2022-12-12; served through the company's sale to Eli Lilly in 2025 (8K-2026-05-08); last Form 4 as CFO on 2025-12-09 (ADV-F4-2025-12-10)
  3. 2021 – now
    Alectorsrc
    Interim CFO (consulting)
    Start 2021-09-08; end date not located
  4. 2018 – now
    Five Prime Therapeuticssrc
    Interim CFO (consulting)
    Start 2018-04-13; end date not located
  5. 2010 – now
    FLG Partners, LLCsrc
    Partner (CFO and board advisory services firm)
    Since September 2010. Permanent or interim CFO of, among others, Apexigen, ArmaGen, Diasome, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas (8K-2026-05-08)

Undated in the sources

  • RDJ Advisorssrc, Sole principal; interim CFO and consulting to life science and SaaS companies
  • Solexasrc, CFO
  • ChemoCentryxsrc, Leadership role
  • Lehman Brotherssrc, Senior Vice President, Global Healthcare Investment Banking Group

Not located: Before September 2010 undated: RDJ Advisors, Solexa, ChemoCentryx and Lehman Brothers years not in any filing read. End dates of the Five Prime and Alector interim roles not located

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family Nektar's 8-K states she has no family relationship with any director or executive officer of the companysrc
  • Boards Director of Biocept Inc. from July 2021 (Form 3; annual director option grants in 2021 and 2022); end date not locatedsrc
  • Investing Bought 100,000 Adverum shares in the open market at about $1.45 on 2023-06-07 while its CFOsrc
  • Other Not a Nektar employee: FLG Partners bills $650/hour for her services; the agreement has no fixed term, ends on 15 days' notice and requires Nektar to indemnify her and FLG. The 8-K says her only related-party interest is her FLG partnershipsrc

Sources12

  1. Filing Nektar Therapeutics 8-K Items 1.01/5.02, interim CFO change (accession 0001193125-26-214976) · 2026-05-08
  2. Filing Form 3, Linda M. Rubinstein (reporting CIK 1321937), Nektar Therapeutics, event 2026-05-15 (0001193125-26-239838) · 2026-05-26
  3. Filing Nektar Therapeutics 10-Q for the quarter ended 2026-06-30, signed by her as interim CFO (0001193125-26-349805) · 2026-08-14
  4. Filing Nektar Therapeutics DEF 14A for the 2026 annual meeting (0001140361-26-016708) · 2026-04-24
  5. Filing Adverum Biotechnologies 8-K Item 5.02, appointment as CFO (0001193125-22-303290) · 2022-12-13
  6. Filing Adverum Biotechnologies DEF 14A, 2023 (0001140361-23-020185) · 2023-04-25
  7. Filing Form 4, Linda M. Rubinstein, Adverum Biotechnologies open-market purchase of 2023-06-07 (0001209191-23-035862) · 2023-06-09
  8. Filing Form 4, Linda M. Rubinstein, Adverum Biotechnologies, dispositions of 2025-12-09 in the Lilly tender (0001321937-25-000005) · 2025-12-10
  9. Filing Form 3, Linda M. Rubinstein, Five Prime Therapeutics, officer title Interim CFO, event 2018-04-13 (0001209191-18-025795) · 2018-04-23
  10. Filing Form 3, Linda M. Rubinstein, Alector Inc., officer title Interim Chief Financial Officer, event 2021-09-08 (0001209191-21-055290) · 2021-09-09
  11. Filing Form 3, Linda M. Rubinstein, Biocept Inc., as director, event 2021-07-16 (0001209191-21-047376); director option grants also on Forms 4 of 2021-07-20 and 2022-09-08 · 2021-07-20
  12. Web search result WebSearch: Linda Rubinstein FLG Partners biography (FLG partner page; summary gives Solexa CFO role and the Solexa sale to Illumina announced November 2006) · 2026-09-25